Search results
Showing 151 to 200 of 1414 results for patients and public
In development [GID-TA10912] Expected publication date: 18 June 2025
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development [GID-TA11373] Expected publication date: TBC
rapid assessment of flu product zanamivir. First public board meeting Register to attend a public board meeting . 2000...
In development [GID-TA11408] Expected publication date: 11 December 2024
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
In development [GID-TA11249] Expected publication date: 18 December 2024
In development [GID-TA11203] Expected publication date: 05 March 2025
Biographies and registered interests for members of the Technology Appraisal Committee A
Guide to the processes of technology appraisal
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
NICE priority methodological research areas.
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
In development [GID-TA11135] Expected publication date: TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development [GID-TA11096] Expected publication date: TBC
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
How voluntary and community sector (VCS) organisations can help us develop guidance
Support for organisations who contribute to developing our guidance
Medical technologies evaluation programme process guide (PMG34)
Medical technologies evaluation programme process guide
Show all sections
- 1 Introduction
- 2 The medical technologies evaluation programme
- 3 Who is involved in the medical technologies evaluation programme
- 4 Identifying, selecting and routing technologies for evaluation
- 5 How medical technologies guidance is developed
- 6 Resolution
- 7 Publishing medical technologies guidance
- 8 Reviews
Awaiting development [GID-DG10087] Expected publication date: TBC
take part in the appraisal and to nominate clinical, commissioning and patient experts . We ask consultees to submit any relevant...
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
In development [GID-TA10904] Expected publication date: 15 January 2025
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
In development [GID-TA11023] Expected publication date: 30 April 2025
In development [GID-TA11174] Expected publication date: 04 December 2024
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
In development [GID-TA10930] Expected publication date: 28 May 2025
Find out more about the types of organisations that can register to be a stakeholder at NICE.
leukaemia, at the Hammersmith Hospital in London. He treated the first UK patients to receive imatinib and continues to be closely...
the NHS or public health service in the UK someone with experience in representing patients or carers, or who is a...
In development [GID-TA11547] Expected publication date: 12 February 2025
The section of the NICE impact lung cancer report looking at how lung cancer is detected.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources
This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.
View quality statements for QS49Show all sections
Sections for QS49
- Quality statements
- Quality statement 1: Personal preparation for surgery
- Quality statement 2: Antibiotic prophylaxis
- Quality statement 3: Patient temperature
- Quality statement 4: Intraoperative staff practices
- Quality statement 5: Information and advice on wound care
- Quality statement 6: Treatment of surgical site infection
- Quality statement 7: Surveillance
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: 11 December 2024
In development [GID-TA11514] Expected publication date: TBC
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]
In development [GID-TA11392] Expected publication date: TBC
things like: making a cut or a hole to gain access to the inside of a patient's body, for example an operation or inserting a tube into...
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
Interventional procedures programme manual
In development [GID-TA10778] Expected publication date: 11 December 2024
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
Interventional Procedures Advisory Committee members
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development [GID-MT599] Expected publication date: TBC
Find out more about quality standards advisory committee 2 members at NICE
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
This quality standard covers managing medicines safely and effectively in care homes. It includes processes for prescribing, handling and administering medicines for adults, young people, and children living in care homes. It also includes providing care and support relating to medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS85Show all sections
Sections for QS85
NHS, local government, social care, patients and their families. Responsible for: clinical guidelines public health...
Support for voluntary and community sector organisations using NICE guidance
A step-by-step timeline of the process we used to develop single technology appraisals (STA)
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
In development [GID-TA11423] Expected publication date: 11 December 2024